- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05468775
Naked Eye 3D Vision Training for the Prevention and Control of Myopia in Adolescents and Children
July 18, 2022 updated by: Yehong Zhuo, Zhongshan Ophthalmic Center, Sun Yat-sen University
The study used children aged 6-18 as subjects to evaluate the efficacy and safety of naked eye 3D vision training for the prevention and control of myopia in adolescents.
A total of 250 subjects were recruited from Zhongshan Ophthalmology Center of Sun Yat-sen University, Shenzhen People's Hospital and Foshan Women's and Children's Hospital, with 1:1 as intervention group and control group.
The study assumes that daily naked eye 3D vision training can effectively control the speed of axial elongation and the progression of myopia.
The main indicators were the use of optical biometrics to detect the subjects' initial axial length and the axial length after 1 month, 3 months and 6 months of intervention.
Secondary indicators were refraction, uncorrected visual acuity, best corrected visual acuity, choroidal thickness, and binocular vision.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
250
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 6~18 years old (including 6 years old and 18 years old), gender is not limited;
- Written informed consent signed by the child and legal guardian has been obtained;
- Patients who have visited the research center in the past month, diagnosed as myopia according to the "Guidelines for the Prevention and Treatment of Myopia" issued by the General Office of the National Health Commission (Guoweiban Medical Letter [2018] No. 393), and the spherical equivalent power is -0.75 to -6.00 Diopter (D) (including -0.75 and -6.00 D);
- Astigmatism≤4.00 D, anisometropia≤4.00 D;
- Monocular international standard logarithmic visual acuity after spectacle correction ≥20/25;
- The subject's guardian can understand the purpose of this study, and the subject can cooperate with the treatment and related eye examinations.
Exclusion Criteria:
- Any eye of the subject suffers from overt strabismus, or any other pathological changes in the eyeball or acute inflammatory disease of the eye;
- Subjects who may suffer from eye diseases that affect vision or refractive errors (such as cataract and other lens damage diseases, glaucoma, macular degeneration, keratopathy, uveitis, retinal detachment, severe vitreous opacity, etc.);
- Systemic diseases: those with a history of immune system diseases, central nervous system diseases, Down syndrome, asthma, severe heart and lung function, severe liver and kidney dysfunction;
- Binocular hyperopia cannot be corrected to logarithmic visual acuity of 20/25;
- The subject has or is undergoing myopia control treatment within the past 1 month, such as atropine eye drops, orthokeratology lenses, progressive lenses, bifocal lenses, etc.;
- Photophobia or unable to open eyes normally due to keratitis, trichiasis, trauma, etc. in any eye of the subjects;
- Subjects participated in other clinical studies 4 weeks before enrollment;
- For safety reasons or the interests of patients, the investigator believes that patients should not participate in other situations in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: control group
|
|
Experimental: intervention group
|
20 minutes of naked eye 3D vision training every day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the change of axial length
Time Frame: baseline, 1st months, 3rd months, 6th months
|
mm
|
baseline, 1st months, 3rd months, 6th months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the change of vision
Time Frame: baseline, 1st months, 3rd months, 6th months
|
Diopter
|
baseline, 1st months, 3rd months, 6th months
|
the change of choroidal thickness
Time Frame: baseline, 1st months, 3rd months, 6th months
|
mm
|
baseline, 1st months, 3rd months, 6th months
|
the change of adjustment range
Time Frame: baseline, 1st months, 3rd months, 6th months
|
Diopter
|
baseline, 1st months, 3rd months, 6th months
|
the change of adjust sensitivity
Time Frame: baseline, 1st months, 3rd months, 6th months
|
cycle per minute
|
baseline, 1st months, 3rd months, 6th months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
August 1, 2022
Primary Completion (Anticipated)
October 1, 2022
Study Completion (Anticipated)
October 1, 2022
Study Registration Dates
First Submitted
July 11, 2022
First Submitted That Met QC Criteria
July 18, 2022
First Posted (Actual)
July 21, 2022
Study Record Updates
Last Update Posted (Actual)
July 21, 2022
Last Update Submitted That Met QC Criteria
July 18, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021KYPJ193
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Axial Elongation
-
Beijing Tongren HospitalUnknownHigh Myopia | Posterior Scleral Reinforcement | Adults | Axial Elongation | Myopia Progression
-
Judson BrandeisUnknown
-
Peking University Cancer Hospital & InstituteCompletedCancer Patients | Feature ElongationChina
-
Marmara UniversityCompleted
-
University of OuluRecruitingBreast Feeding | Frenulum Breve | Tongue Tie | Frenulum; ElongationFinland
-
Shanghai Eye Disease Prevention and Treatment CenterTongji Hospital; Sichuan Provincial People's Hospital; The Affiliated Hospital... and other collaboratorsNot yet recruiting
-
UCB Biopharma SRLCompletedNonradiographic Axial SpondyloarthritisUnited States, Belgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Poland, Spain, Turkey, United Kingdom
-
Novartis PharmaceuticalsActive, not recruitingNon-radiographic Axial SpondyloarthritisChina
-
Novartis PharmaceuticalsRecruitingNon-radiographic Axial SpondyloarthritisBelgium, Netherlands, Italy, Thailand, Hungary, Malaysia, Germany, Israel, France, Czechia, Colombia, Romania, Poland, Turkey, Vietnam, Brazil, Mexico, Philippines
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Not yet recruitingAxial SpondyloarthritisChina
Clinical Trials on Naked eye 3D vision training
-
Rigshospitalet, DenmarkCompleted
-
VA Office of Research and DevelopmentTerminated
-
Rebiscan, Inc.University of Southern CaliforniaCompletedStrabismus | AmblyopiaUnited States
-
Retina Implant AGCompletedRetinal Degeneration | Retinitis PigmentosaGermany, Hungary, United Kingdom
-
Shahid Beheshti University of Medical SciencesRecruitingConvergence InsufficiencyIran, Islamic Republic of
-
University of California, BerkeleyNational Eye Institute (NEI)Completed
-
OculoMotor TechnologiesSalus University; New Jersey Institute of TechnologyRecruitingConvergence InsufficiencyUnited States
-
Stanford UniversityCompletedPain | Vision NearsightedUnited States
-
University of MagdeburgCompletedBrain Injuries, Traumatic | HemianopiaGermany